Metastatic pancreatic cancer: Mechanisms and detection (Review)
- Authors:
- Xiangling Chen
- Fangfang Liu
- Qingping Xue
- Xiechuan Weng
- Fan Xu
-
Affiliations: Department of Public Health, Chengdu Medical College, Chengdu, Sichuan 610500, P.R. China, Department of Art, Art College, Southwest Minzu University, Chengdu, Sichuan 610041, P.R. China, Department of Neuroscience, Beijing Institute of Basic Medical Sciences, Beijing 100850, P.R. China - Published online on: September 7, 2021 https://doi.org/10.3892/or.2021.8182
- Article Number: 231
-
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Rawla P, Sunkara T and Gaduputi V: Epidemiology of pancreatic cancer: Global trends, etiology and risk factors. World J Oncol. 10:10–27. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W and Palmer DH: Therapeutic developments in pancreatic cancer: Current and future perspectives. Nat Rev Gastroenterol Hepatol. 15:333–348. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C and Thun MJ: Cancer Statistics, 2006. CA Cancer J Clin. 56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Malvezzi M, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2013. Ann Oncol. 24:792–800. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Zhang J, Wang H, Gao P, Singh M, Shen K and Fang N: Angiotensin II downregulates catalase expression and activity in vascular adventitial fibroblasts through an AT1R/ERK1/2-dependent pathway. Mol Cell Biochem. 358:21–29. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki T, Sato T, Nakai Y, Sasahira N, Isayama H and Koike K: Brain metastasis in pancreatic cancer: Two case reports. Medicine (Baltimore). 98:e142272019. View Article : Google Scholar : PubMed/NCBI | |
|
Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B, Zhou L, Song WJ and Dou KF: MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. Int J Biol Sci. 10:733–745. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB III, Binder E, Cardin DB, Cha C, et al: Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 15:1028–1061. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, et al: Pancreatic adenocarcinoma, version 1.2019. J Natl Compr Canc Netw. 17:202–210. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, et al: Metastatic pancreatic cancer: ASCO Guideline Update. J Clin Oncol. Aug 5–2020.(Epub ahead of print). doi: 10.1200/JCO.20.01364. View Article : Google Scholar : PubMed/NCBI | |
|
Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC and Borrebaeck CA: Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 36:2887–2894. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee ES and Lee JM: Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol. 20:7864–7877. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Singhi AD, Koay EJ, Chari ST and Maitra A: Early detection of pancreatic cancer: Opportunities and challenges. Gastroenterology. 156:2024–2040. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Garces-Descovich A, Beker K, Jaramillo-Cardoso A, James Moser A and Mortele KJ: Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: Analysis and pitfalls. Abdom Radiol (NY). 43:314–322. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zins M, Matos C and Cassinotto C: Pancreatic adenocarcinoma staging in the Era of preoperative chemotherapy and radiation therapy. Radiology. 287:374–390. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wong JC and Lu DS: Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 6:1301–1308. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sah RP, Sharma A, Nagpal S, Patlolla SH, Sharma A, Kandlakunta H, Anani V, Angom RS, Kamboj AK, Ahmed N, et al: Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology. 156:1742–1752. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, et al: Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature. 558:600–604. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng SH, Cheng YJ, Jin ZY and Xue HD: Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. Eur J Radiol. 113:188–197. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamed E, Needham A, Psarelli E, Carroll M, Vinjamuri S, Sanghera B, Wong WL, Halloran C and Ghaneh P: Prognostic value of (18)FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Eur J Surg Oncol. 46:1532–1538. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, Kang KW, Chung JK, Kim EE and Lee DS: Prognostic value of metabolic and volumetric parameters of preoperative FDG-PET/CT in patients with resectable pancreatic cancer. Medicine (Baltimore). 95:e36862016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S and Liao M: Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 96:e78132017. View Article : Google Scholar : PubMed/NCBI | |
|
Kim MJ, Lee KH, Lee KT, Lee JK, Ku BH, Oh CR, Heo JS, Choi SH and Choi DW: The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Pancreas. 41:897–903. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu S, Zhang J, Zuo C, Cheng C, Liu Q and Sun G: (18)F-FDG-PET/CT findings in pancreatic metastasis. Radiol Med. 120:887–898. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gao G, Gong B and Shen W: Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: Comparison with 18FDG PET alone and CT alone. Surg Oncol. 22:195–200. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, Teramoto N, Yamamoto K, Inoue T and Iguchi H: Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: Impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 42:11–19. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Callery MP, Chang KJ, Fishman EK, Talamonti MS, William Traverso L and Linehan DC: Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement. Ann Surg Oncol. 16:1727–1733. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bae JS, Kim JH, Joo I, Chang W and Han JK: MDCT findings predicting post-operative residual tumor and survival in patients with pancreatic cancer. Eur Radiol. 29:3714–3724. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Raman SP, Reddy S, Weiss MJ, Manos LL, Cameron JL, Zheng L, Herman JM, Hruban RH, Fishman EK and Wolfgang CL: Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol. 204:W37–W42. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ichikawa T, Haradome H, Hachiya J, Nitatori T, Ohtomo K, Kinoshita T and Araki T: Pancreatic ductal adenocarcinoma: Preoperative assessment with helical CT versus dynamic MR imaging. Radiology. 202:655–662. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Chen FM, Ni JM, Zhang ZY, Zhang L, Li B and Jiang CJ: Presurgical evaluation of pancreatic cancer: A comprehensive imaging comparison of CT versus MRI. Am J Roentgenol. 206:526–535. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sheridan MB, Ward J, Guthrie JA, Spencer JA, Craven CM, Wilson D, Guillou PJ and Robinson PJ: Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: A comparative study with receiver operating characteristic analysis. AJR Am J Roentgenol. 173:583–590. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, Nio Y, Schulick RS, Bassi C, Kluijt I, et al: International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 62:339–347. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira SP, Oldfield L, Ney A, Hart PA, Keane MG, Pandol SJ, Li D, Greenhalf W, Jeon CY, Koay EJ, et al: Early detection of pancreatic cancer. Lancet Gastroenterol Hepatol. 5:698–710. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, Topazian M, Takahashi N, Fletcher J, Petersen G, et al: Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 142:796–804. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mizumoto T, Toyama H, Terai S, Mukubou H, Yamashita H, Shirakawa S, Nanno Y, Sofue K, Kido M, Ajiki T and Fukumoto T: Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics. Pancreatology. 17:956–961. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Leng KM, Wang ZD, Zhao JB, Cui YF and Zhong XY: Impact of pancreatic margin status and lymph node metastases on recurrence after resection for invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas: A meta-analysis. Dig Surg. 29:213–225. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Mohamed A, Ayav A, Belle A, Orry X, Chevaux JB and Laurent V: Pancreatic cancer in patients with chronic calcifying pancreatitis: Computed tomography findings-a retrospective analysis of 48 patients. Eur J Radiol. 86:206–212. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Riviere DM, van Geenen EJM, van der Kolk BM, Nagtegaal ID, Radema SA, van Laarhoven CJHM and Hermans JJ: Improving preoperative detection of synchronous liver metastases in pancreatic cancer with combined contrast-enhanced and diffusion-weighted MRI. Abdom Radiol (NY). 44:1756–1765. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Farag A, Le Lu, Roth HR, Liu J, Turkbey E and Summers RM: A Bottom-up approach for pancreas segmentation using cascaded superpixels and (Deep) image patch labeling. IEEE Trans Image Process. 26:386–399. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Karasawa K, Oda M, Kitasaka T, Misawa K, Fujiwara M, Chu C, Zheng G, Rueckert D and Mori K: Multi-atlas pancreas segmentation: Atlas selection based on vessel structure. Med Image Anal. 39:18–28. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gou S, Lee P, Hu P, Rwigema JC and Sheng K: Feasibility of automated 3-dimensional magnetic resonance imaging pancreas segmentation. Adv Radiat Oncol. 1:182–193. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chu LC, Goggins MG and Fishman EK: Diagnosis and detection of pancreatic cancer. Cancer J. 23:333–342. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, Macari M, Megibow AJ, Miller FH, Mortele KJ, et al: Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 146:291–304.e1. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Laffan TA, Horton KM, Klein AP, Berlanstein B, Siegelman SS, Kawamoto S, Johnson PT, Fishman EK and Hruban RH: Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 191:802–807. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KS, Sekhar A, Rofsky NM and Pedrosa I: Prevalence of incidental pancreatic cysts in the adult population on MR imaging. Am J Gastroenterol. 105:2079–2084. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Y, Zhang H, Chen N, Hao J, Jin H and Ma X: Diagnostic value of various liquid biopsy methods for pancreatic cancer: A systematic review and meta-analysis. Medicine (Baltimore). 99:e185812020. View Article : Google Scholar : PubMed/NCBI | |
|
Kamyabi N, Bernard V and Maitra A: Liquid biopsies in pancreatic cancer. Expert Rev Anticancer Ther. 19:869–878. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kunovsky L, Tesarikova P, Kala Z, Kroupa R, Kysela P, Dolina J and Trna J: The use of biomarkers in early diagnostics of pancreatic cancer. Can J Gastroenterol Hepatol. 2018:53898202018. View Article : Google Scholar : PubMed/NCBI | |
|
Sefrioui D, Blanchard F, Toure E, Basile P, Beaussire L, Dolfus C, Perdrix A, Paresy M, Antonietti M, Iwanicki-Caron I, et al: Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 117:1017–1025. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Ariston Gabriel AN, Wang F, Jiao Q, Yvette U, Yang X, Al-Ameri SA, Du L, Wang YS and Wang C: The involvement of exosomes in the diagnosis and treatment of pancreatic cancer. Mol Cancer. 19:1322020. View Article : Google Scholar : PubMed/NCBI | |
|
Dhara S, Chhangawala S, Chintalapudi H, Askan G, Aveson V, Massa AL, Zhang L, Torres D, Makohon-Moore AP, Lecomte N, et al: Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Nat Commun. 12:30442021. View Article : Google Scholar : PubMed/NCBI | |
|
Lamouille S, Xu J and Derynck R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 15:178–196. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Sannino G, Armbruster N, Bodenhöfer M, Haerle U, Behrens D, Buchholz M, Rothbauer U, Sipos B and Schmees C: Role of BCL9L in transforming growth factor-β (TGF-β)-induced epithelial-to-mesenchymal-transition (EMT) and metastasis of pancreatic cancer. Oncotarget. 7:73725–73738. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ye X and Weinberg RA: Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Oberstein PE and Olive KP: Pancreatic cancer: Why is it so hard to treat? Therap Adv Gastroenterol. 6:321–337. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Carbone C and Melisi D: NF-κB as a target for pancreatic cancer therapy. Expert Opin Ther Targets. 16 (Suppl 2):S1–S10. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pires BR, Mencalha AL, Ferreira GM, de Souza WF, Morgado-Díaz JA, Maia AM, Corrêa S and Abdelhay ES: NF-kappaB is involved in the regulation of EMT genes in breast cancer cells. PLoS One. 12:e01696222017. View Article : Google Scholar : PubMed/NCBI | |
|
Labelle M, Begum S and Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 20:576–590. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Buscail L, Bournet B and Cordelier P: Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenrerol Hepatol. 17:153–168. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang J, Li S, Li J, Wang F, Chen K, Zheng Y, Wang J, Lu W, Zhou Y, Yin Q, et al: A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer. Pancreatology. 16:605–614. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Dong L, Wang S, Fu B and Wang J: Evaluation of droplet digital PCR and next generation sequencing for characterizing DNA reference material for KRAS mutation detection. Sci Rep. 8:96502018. View Article : Google Scholar : PubMed/NCBI | |
|
Patel SA and Vanharanta S: Epigenetic determinants of metastasis. Mol Oncol. 11:79–96. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Thålin C, Hisada Y, Lundström S, Mackman N and Wallén H: Neutrophil extracellular traps: Villains and targets in arterial, venous, and cancer-associated thrombosis. Arterioscler Thromb Vasc Biol. 39:1724–1738. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pastushenko I, Brisebarre A, Sifrim A, Fioramonti M, Revenco T, Boumahdi S, Van Keymeulen A, Brown D, Moers V, Lemaire S, et al: Identification of the tumour transition states occurring during EMT. Nature. 556:463–468. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Murthy P, Singhi AD, Ross MA, Loughran P, Paragomi P, Papachristou GI, Whitcomb DC, Zureikat AH, Lotze MT, Zeh Iii HJ and Boone BA: Enhanced neutrophil extracellular trap formation in acute pancreatitis contributes to disease severity and is reduced by chloroquine. Front Immunol. 10:282019. View Article : Google Scholar : PubMed/NCBI | |
|
Kajioka H, Kagawa S, Ito A, Yoshimoto M, Sakamoto S, Kikuchi S, Kuroda S, Yoshida R, Umeda Y, Noma K, et al: Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Cancer Let. 497:1–13. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang K, Sun X, Zhou X, Han L, Chen L, Shi Z, Zhang A, Ye M, Wang Q, Liu C, et al: Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner. Oncotarget. 6:537–546. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jiao F, Hu H, Han T, Yuan C and Wang L, Jin Z, Guo Z and Wang L: Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci. 16:6677–6693. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun YW, Chen YF, Li J, Huo YM, Liu DJ, Hua R, Zhang JF, Liu W, Yang JY, Fu XL, et al: A novel long non-coding RNA ENST00000480739 suppresses tumour cell invasion by regulating OS-9 and HIF-1alpha in pancreatic ductal adenocarcinoma. Br J Cancer. 111:2131–2141. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Y, Chen J, Zhou Y, Fu Z, Zhou Q, Wang Y, Gao W, Zheng S, Zhao X, Chen T and Chen R: High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. J Transl Med. 13:1372015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Zhi X, Gao Y, Ta N, Jiang H and Zheng J: LncRNAs in pancreatic cancer. Oncotarget. 7:57379–57390. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Jiang XM, Feng ZX, Li XL and Zhang WL: Long noncoding RNA PCAT-1 accelerates the metastasis of pancreatic cancer by repressing RBM5. Eur Rev Med Pharmacol Sci. 23:7350–7355. 2019.PubMed/NCBI | |
|
Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M, Pinto E and Roviello F: CA19-9 serum levels in obstructive jaundice: Clinical value in benign and malignant conditions. Am J Surg. 198:333–339. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Shang X, Song C, Du X, Shao H, Xu D and Wang X: The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control. Saudi Med J. 38:204–208. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yoshida H, Onda M, Tajiri T, Mamada Y, Taniai N, Mineta S, Hirakata A, Futami R, Arima Y, Inoue M, et al: Infected hepatic cyst. Hepatogastroenterology. 50:507–509. 2003.PubMed/NCBI | |
|
Zhai H, Huang J, Yang C, Fu Y and Yang B: Serum CEA and CA19-9 levels are associated with the presence and severity of colorectal neoplasia. Clin Lab. 64:351–356. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ballehaninna UK and Chamberlain RS: The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 3:105–119. 2012.PubMed/NCBI | |
|
Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB III, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, et al: Pancreatic adenocarcinoma. J Natl Compr Canc Netw. 8:972–1017. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Kimmey MB, Bronner MP, Byrd DR and Brentnall TA: Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc. 56 (Suppl 4):S82–S86. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, et al: Management of patients with increased risk for familial pancreatic cancer: Updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 69:7–17. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, Zhang H and Li Z: Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies. Eur J Cancer. 47:1928–1937. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kirkegård J, Mortensen FV and Cronin-Fenton D: Chronic pancreatitis and pancreatic cancer risk: A systematic review and Meta-analysis. Am J Gastroenterol. 112:1366–1372. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Gaiser RA, Halimi A, Alkharaan H, Lu L, Davanian H, Healy K, Hugerth LW, Ateeb Z, Valente R, Fernández Moro C, et al: Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cance. Gut. 68:2186–2194. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Duraker N, Hot S, Polat Y, Höbek A, Gençler N and Urhan N: CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 95:142–147. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ III and Hogg ME: CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: Predicting recurrence and changing prognosis over time. Ann Surg Oncol. 25:3483–3491. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Azizian A, Rühlmann F, Krause T, Bernhardt M, Jo P, König A, Kleiß M, Leha A, Ghadimi M and Gaedcke J: CA19-9 for detecting recurrence of pancreatic cancer. Sci Rep. 10:13322020. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C and Warshaw AL: Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 24:2897–2902. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB III, MacDonald J and Willett CG: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol. 26:5918–5922. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Jia F, Liu M, Li X, Zhang F, Yue S and Liu J: Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance. World J Surg Oncol. 17:1632019. View Article : Google Scholar : PubMed/NCBI | |
|
Moro L, Simoneschi D, Kurz E, Arbini AA, Jang S, Guaragnella N, Giannattasio S, Wang W, Chen YA, Pires G, et al: Epigenetic silencing of the ubiquitin ligase subunit FBXL7 impairs c-SRC degradation and promotes epithelial-to-mesenchymal transition and metastasis. Nat Cell Biol. 22:1130–1142. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Moro L and Pagano M: Epigenetic suppression of FBXL7 promotes metastasis. Mol Cell Oncol. 7:18336982020. View Article : Google Scholar : PubMed/NCBI | |
|
Baumert M, Surmiak P, Szymkowiak M and Janosz A: The assessment of Pentraxin 3: A novel biomarker in early detection of infection in newborns. Biomed Res Int. 2021:66386222021. View Article : Google Scholar : PubMed/NCBI | |
|
Goulart MR, Watt J, Siddiqui I, Lawlor RT, Imrali A, Hughes C, Saad A, ChinAleong J, Hurt C, Cox C, et al: Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 5:612021. View Article : Google Scholar : PubMed/NCBI | |
|
Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, et al: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med. 22:497–505. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Vennin C, Murphy KJ, Morton JP, Cox TR, Pajic M and Timpson P: Reshaping the tumor stroma for treatment of pancreatic cancer. Gastroenterology. 154:820–838. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kim EJ, Sahai V, Abel EV, Griffith KA, Greenson JK, Takebe N, Khan GN, Blau JL, Craig R, Balis UG, et al: Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 20:5937–5945. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, et al: Randomized Phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 33:4284–4292. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, et al: A phase I study of FOLFIRINOX Plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas. 45:370–375. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ramanathan RK, McDonough S, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, Chiorean EG, Shields AF, Behl D, et al: Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 37:1062–1069. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wang WQ, Liu L, Xu JZ and Yu XJ: Reflections on depletion of tumor stroma in pancreatic cancer. Biochim Biophys Acta Rev Cancer. 1871:267–272. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, Laklai H, Sugimoto H, Kahlert C, Novitskiy SV, et al: Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 28:831–833. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al: Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci USA. 111:E3091–E3100. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Roberts KJ, Kershner AM and Beachy PA: The stromal niche for epithelial stem cells: A template for regeneration and a brake on malignancy. Cancer Cell. 32:404–410. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lin Z, Lu S, Xie X, Yi X and Huang H: Noncoding RNAs in drug-resistant pancreatic cancer: A review. Biomed Pharmacother. 131:1107682020. View Article : Google Scholar : PubMed/NCBI | |
|
Peng Y and Croce CM: The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 1:150042016. View Article : Google Scholar : PubMed/NCBI | |
|
Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Khan IA, Rashid S, Singh N, Rashid S, Singh V, Gunjan D, Das P, Dash NR, Pandey RM, Chauhan SS, et al: Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma. Sci Rep. 11:28242021. View Article : Google Scholar : PubMed/NCBI | |
|
Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P and Taubert H: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 126:73–80. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wojdemann M and Johansen JS: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer-five microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ye ZQ, Zou CL, Chen HB, Jiang MJ, Mei Z and Gu DN: MicroRNA-7 as a potential biomarker for prognosis in pancreatic cancer. Dis Markers. 2020:27821012020. View Article : Google Scholar : PubMed/NCBI | |
|
Kumarswamy R, Volkmann I and Thum T: Regulation and function of miRNA-21 in health and disease. RNA Biol. 8:706–713. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu R, Zhang H, Wang X, Zhou L, Li H, Deng T, Qu Y, Duan J, Bai M, Ge S, et al: The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma. Oncotarget. 6:43831–43842. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Jamaluddin MS, Weakley SM, Yao Q and Chen C: Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg. 35:1725–1731. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, Mullendore ME, Goggins MG, Hong SM and Maitra A: MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 8:340–346. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT and Giaccia AJ: Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 35:856–867. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wu X, Wang Y, Yu T, Nie E, Hu Q, Wu W, Zhi T, Jiang K, Wang X, Lu X, et al: Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma. Neurooncology. 19:1195–1205. 2017. | |
|
Korpal M, Lee ES, Hu G and Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Luthra R, Singh RR, Luthra MG, Li YX, Hannah C, Romans AM, Barkoh BA, Chen SS, Ensor J, Maru DM, et al: MicroRNA-196a targets annexin A1: A microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene. 27:6667–6678. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ma Y, Yu S, Zhao W, Lu Z and Chen J: miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 298:150–158. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Du J, Zheng X, Cai S, Zhu Z, Tan J, Hu B, Huang Z and Jiao H: MicroRNA-506 participates in pancreatic cancer pathogenesis by targeting PIM3. Mol Med Rep. 12:5121–5126. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z, Chen LY, Dai HY, Wang P, Gao S and Wang K: miR-301a promotes pancreatic cancer cell proliferation by directly inhibiting Bim expression. J Cell Biochem. 113:3229–3235. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Y, Liu X, Chen Q, Liu T, Lu C, Yu J, Miao Y and Wei J: Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4. J Exp Clin Cancer Res. 37:1302018. View Article : Google Scholar : PubMed/NCBI | |
|
Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T and Chen P: MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. Tumour Biol. 37:14813–14824. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Fu XF, Zhao HC, Yang CL, Chen CZ, Wang K, Gao F, Tian YZ and Zhao HL: MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. Oncol Lett. 22:6262021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G, Ji L, Ke M, Ou Z, Tang N and Li Y: miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Biomed Pharmacother. 106:523–531. 2018. View Article : Google Scholar : PubMed/NCBI |
